Literature DB >> 25242043

Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS.

Rebekka K Schneider1, Vera Ademà2, Dirk Heckl1, Marcus Järås1, Mar Mallo3, Allegra M Lord1, Lisa P Chu1, Marie E McConkey1, Rafael Kramann4, Ann Mullally1, Rafael Bejar5, Francesc Solé3, Benjamin L Ebert6.   

Abstract

The casein kinase 1A1 gene (CSNK1A1) is a putative tumor suppressor gene located in the common deleted region for del(5q) myelodysplastic syndrome (MDS). We generated a murine model with conditional inactivation of Csnk1a1 and found that Csnk1a1 haploinsufficiency induces hematopoietic stem cell expansion and a competitive repopulation advantage, whereas homozygous deletion induces hematopoietic stem cell failure. Based on this finding, we found that heterozygous inactivation of Csnk1a1 sensitizes cells to a CSNK1 inhibitor relative to cells with two intact alleles. In addition, we identified recurrent somatic mutations in CSNK1A1 on the nondeleted allele of patients with del(5q) MDS. These studies demonstrate that CSNK1A1 plays a central role in the biology of del(5q) MDS and is a promising therapeutic target.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25242043      PMCID: PMC4199102          DOI: 10.1016/j.ccr.2014.08.001

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  50 in total

Review 1.  Molecular dissection of the 5q deletion in myelodysplastic syndrome.

Authors:  Benjamin L Ebert
Journal:  Semin Oncol       Date:  2011-10       Impact factor: 4.929

Review 2.  Casein kinase 1: Complexity in the family.

Authors:  Jit Kong Cheong; David M Virshup
Journal:  Int J Biochem Cell Biol       Date:  2010-12-09       Impact factor: 5.085

Review 3.  Advances in the 5q- syndrome.

Authors:  Jacqueline Boultwood; Andrea Pellagatti; Andrew N J McKenzie; James S Wainscoat
Journal:  Blood       Date:  2010-08-23       Impact factor: 22.113

4.  Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome.

Authors:  Madhu S Kumar; Anupama Narla; Atsushi Nonami; Ann Mullally; Nadya Dimitrova; Brian Ball; J Randall McAuley; Luke Poveromo; Jeffrey L Kutok; Naomi Galili; Azra Raza; Eyal Attar; D Gary Gilliland; Tyler Jacks; Benjamin L Ebert
Journal:  Blood       Date:  2011-08-26       Impact factor: 22.113

5.  The 'just-right' signaling model: APC somatic mutations are selected based on a specific level of activation of the beta-catenin signaling cascade.

Authors:  Cristina Albuquerque; Cor Breukel; Rob van der Luijt; Paulo Fidalgo; Pedro Lage; Frederik J M Slors; C Nobre Leitão; Riccardo Fodde; Ron Smits
Journal:  Hum Mol Genet       Date:  2002-06-15       Impact factor: 6.150

6.  CKIα ablation highlights a critical role for p53 in invasiveness control.

Authors:  Ela Elyada; Ariel Pribluda; Robert E Goldstein; Yael Morgenstern; Guy Brachya; Gady Cojocaru; Irit Snir-Alkalay; Ido Burstain; Rebecca Haffner-Krausz; Steffen Jung; Zoltan Wiener; Kari Alitalo; Moshe Oren; Eli Pikarsky; Yinon Ben-Neriah
Journal:  Nature       Date:  2011-02-17       Impact factor: 49.962

7.  Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells.

Authors:  Shilpee Dutt; Anupama Narla; Katherine Lin; Ann Mullally; Nirmalee Abayasekara; Christine Megerdichian; Frederick H Wilson; Treeve Currie; Arati Khanna-Gupta; Nancy Berliner; Jeffery L Kutok; Benjamin L Ebert
Journal:  Blood       Date:  2010-11-10       Impact factor: 22.113

8.  Canonical wnt signaling regulates hematopoiesis in a dosage-dependent fashion.

Authors:  Tiago C Luis; Brigitta A E Naber; Paul P C Roozen; Martijn H Brugman; Edwin F E de Haas; Mehrnaz Ghazvini; Willem E Fibbe; Jacques J M van Dongen; Riccardo Fodde; Frank J T Staal
Journal:  Cell Stem Cell       Date:  2011-10-04       Impact factor: 24.633

9.  Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes.

Authors:  Timothy A Graubert; Dong Shen; Li Ding; Theresa Okeyo-Owuor; Cara L Lunn; Jin Shao; Kilannin Krysiak; Christopher C Harris; Daniel C Koboldt; David E Larson; Michael D McLellan; David J Dooling; Rachel M Abbott; Robert S Fulton; Heather Schmidt; Joelle Kalicki-Veizer; Michelle O'Laughlin; Marcus Grillot; Jack Baty; Sharon Heath; John L Frater; Talat Nasim; Daniel C Link; Michael H Tomasson; Peter Westervelt; John F DiPersio; Elaine R Mardis; Timothy J Ley; Richard K Wilson; Matthew J Walter
Journal:  Nat Genet       Date:  2011-12-11       Impact factor: 38.330

10.  Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo.

Authors:  Petter S Woll; Una Kjällquist; Onima Chowdhury; Helen Doolittle; David C Wedge; Supat Thongjuea; Rikard Erlandsson; Mtakai Ngara; Kristina Anderson; Qiaolin Deng; Adam J Mead; Laura Stenson; Alice Giustacchini; Sara Duarte; Eleni Giannoulatou; Stephen Taylor; Mohsen Karimi; Christian Scharenberg; Teresa Mortera-Blanco; Iain C Macaulay; Sally-Ann Clark; Ingunn Dybedal; Dag Josefsen; Pierre Fenaux; Peter Hokland; Mette S Holm; Mario Cazzola; Luca Malcovati; Sudhir Tauro; David Bowen; Jacqueline Boultwood; Andrea Pellagatti; John E Pimanda; Ashwin Unnikrishnan; Paresh Vyas; Gudrun Göhring; Brigitte Schlegelberger; Magnus Tobiasson; Gunnar Kvalheim; Stefan N Constantinescu; Claus Nerlov; Lars Nilsson; Peter J Campbell; Rickard Sandberg; Elli Papaemmanuil; Eva Hellström-Lindberg; Sten Linnarsson; Sten Eirik W Jacobsen
Journal:  Cancer Cell       Date:  2014-05-15       Impact factor: 31.743

View more
  71 in total

1.  Haploinsufficient loss of multiple 5q genes may fine-tune Wnt signaling in del(5q) therapy-related myeloid neoplasms.

Authors:  Angela Stoddart; Joy Nakitandwe; Shann-Ching Chen; James R Downing; Michelle M Le Beau
Journal:  Blood       Date:  2015-11-13       Impact factor: 22.113

2.  Pharmacological inhibition of the transcription factor PU.1 in leukemia.

Authors:  Iléana Antony-Debré; Ananya Paul; Joana Leite; Kelly Mitchell; Hye Mi Kim; Luis A Carvajal; Tihomira I Todorova; Kenneth Huang; Arvind Kumar; Abdelbasset A Farahat; Boris Bartholdy; Swathi-Rao Narayanagari; Jiahao Chen; Alberto Ambesi-Impiombato; Adolfo A Ferrando; Ioannis Mantzaris; Evripidis Gavathiotis; Amit Verma; Britta Will; David W Boykin; W David Wilson; Gregory Mk Poon; Ulrich Steidl
Journal:  J Clin Invest       Date:  2017-10-30       Impact factor: 14.808

3.  CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma.

Authors:  Ajinkya Patil; Mark Manzano; Eva Gottwein
Journal:  Blood       Date:  2018-06-28       Impact factor: 22.113

4.  Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase.

Authors:  Georg Petzold; Eric S Fischer; Nicolas H Thomä
Journal:  Nature       Date:  2016-02-24       Impact factor: 49.962

5.  Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q.

Authors:  M Heuser; M Meggendorfer; M M A Cruz; J Fabisch; S Klesse; L Köhler; G Göhring; C Ganster; K Shirneshan; A Gutermuth; S Cerny-Reiterer; J Krönke; V Panagiota; C Haferlach; C Koenecke; U Platzbecker; C Thiede; T Schroeder; G Kobbe; S Ehrlich; K Stamer; K Döhner; P Valent; B Schlegelberger; N Kroeger; A Ganser; D Haase; T Haferlach; F Thol
Journal:  Leukemia       Date:  2015-02-24       Impact factor: 11.528

6.  Expression of the IFNAR1 chain of type 1 interferon receptor in benign cells protects against progression of acute leukemia.

Authors:  Bin Zhao; Sabyasachi Bhattacharya; Qiujing Yu; Serge Y Fuchs
Journal:  Leuk Lymphoma       Date:  2017-05-15

Review 7.  Targeted Protein Degradation by Small Molecules.

Authors:  Daniel P Bondeson; Craig M Crews
Journal:  Annu Rev Pharmacol Toxicol       Date:  2016-10-12       Impact factor: 13.820

Review 8.  Genetics of MDS.

Authors:  Seishi Ogawa
Journal:  Blood       Date:  2019-01-22       Impact factor: 22.113

9.  Activating p53 and Inhibiting Superenhancers to Cure Leukemia.

Authors:  Brian Ball; Omar Abdel-Wahab
Journal:  Trends Pharmacol Sci       Date:  2018-12       Impact factor: 14.819

10.  A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia.

Authors:  Daniel J DeAngelo; Andrew M Brunner; Lillian Werner; David Avigan; Amir T Fathi; Adam S Sperling; Abigail Washington; Dina Stroopinsky; Jacalyn Rosenblatt; Malgorzata McMasters; Katarina Luptakova; Martha Wadleigh; David P Steensma; Gabriela S Hobbs; Eyal C Attar; Philip C Amrein; Benjamin L Ebert; Richard M Stone; Karen K Ballen
Journal:  Am J Hematol       Date:  2017-11-21       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.